OPKO Health (NASDAQ:OPK) Shares Up 5.1%

Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) were up 5.1% during trading on Monday . The company traded as high as $1.42 and last traded at $1.42. Approximately 3,724,547 shares traded hands during trading, a decline of 75% from the average daily volume of 14,676,670 shares. The stock had previously closed at $1.35.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OPK shares. Piper Sandler reaffirmed an "overweight" rating and issued a $5.00 target price on shares of OPKO Health in a report on Monday, April 1st. StockNews.com cut OPKO Health from a "hold" rating to a "sell" rating in a report on Friday, March 1st. HC Wainwright reiterated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. Finally, Barrington Research reissued an "outperform" rating and set a $1.50 price objective on shares of OPKO Health in a report on Monday, April 1st.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. The stock has a market cap of $975.79 million, a PE ratio of -5.60 and a beta of 1.81. The stock's 50-day moving average is $1.03 and its two-hundred day moving average is $1.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The firm had revenue of $181.90 million during the quarter, compared to analyst estimates of $177.53 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. OPKO Health's revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities analysts predict that OPKO Health, Inc. will post -0.33 earnings per share for the current year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was acquired at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the purchase, the chief executive officer now owns 210,968,225 shares of the company's stock, valued at $183,542,355.75. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock in a transaction on Monday, March 18th. The shares were purchased at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the purchase, the chief executive officer now directly owns 210,968,225 shares of the company's stock, valued at approximately $183,542,355.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard M. Krasno acquired 30,000 shares of OPKO Health stock in a transaction on Monday, January 29th. The shares were bought at an average price of $0.99 per share, for a total transaction of $29,700.00. Following the completion of the purchase, the director now directly owns 103,333 shares in the company, valued at $102,299.67. The disclosure for this purchase can be found here. Over the last three months, insiders bought 6,691,531 shares of company stock worth $6,384,039. 47.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its holdings in shares of OPKO Health by 300.4% during the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company's stock worth $8,263,000 after purchasing an additional 3,874,519 shares during the period. SG Americas Securities LLC increased its holdings in shares of OPKO Health by 19.3% in the 4th quarter. SG Americas Securities LLC now owns 244,294 shares of the biotechnology company's stock worth $369,000 after acquiring an additional 39,459 shares during the period. EP Wealth Advisors LLC increased its holdings in shares of OPKO Health by 140.3% in the 3rd quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 18,041 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of OPKO Health by 7.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 5,549,946 shares of the biotechnology company's stock valued at $8,880,000 after purchasing an additional 405,106 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of OPKO Health by 17.4% during the 3rd quarter. Barclays PLC now owns 188,421 shares of the biotechnology company's stock valued at $302,000 after purchasing an additional 27,946 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.